Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Igm Biosciences Inc (IGMS)

Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Snowflake Stock Jumps Over 21% In Premarket Following Beat-and-Raise Q3: Retail Brace For ‘Parabolic’ Run Stocktwits - Thu Nov 21, 5:38AM CST

Snowflake CEO Sridhar Ramaswamy said, “Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform.”

SNOW : 166.29 (+1.27%)
IGMS : 6.90 (-2.13%)
IWL : 146.00 (+1.04%)
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Fri Nov 8, 6:00AM CST

IGMS : 6.90 (-2.13%)
IGM Biosciences to Present at Three Upcoming Investor Conferences GlobeNewswire - Mon Nov 4, 6:00AM CST

IGMS : 6.90 (-2.13%)
Wall Street - Trader at NYSE by Orhan Akkurt via Shutterstock
Stock Index Futures Mixed Ahead of U.S. JOLTs Report and Fed Speak, Nike Earnings on Tap Barchart - Tue Oct 1, 4:41AM CDT

December S&P 500 E-Mini futures (ESZ24) are down -0.13%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.06% this morning as investors awaited the latest reading on U.S. job openings, comments...

CVS : 44.36 (+1.32%)
AAPL : 254.49 (+1.88%)
MKC : 78.86 (+0.79%)
IGMS : 6.90 (-2.13%)
F : 9.88 (+1.44%)
NQZ24 : 20,947.98s (-0.78%)
MU : 90.12 (+3.48%)
HPQ : 32.94 (+1.48%)
NKE : 76.94 (-0.21%)
1COV.D.DX : 57.100 (-0.10%)
PAYX : 139.54 (+1.26%)
UPS : 125.68 (+2.47%)
Change in Medivir's Board of Directors PR Newswire - Fri Oct 20, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

IGMS : 6.90 (-2.13%)
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 6.90 (-2.13%)
Medivir to present at the Pareto Securities Healthcare Conference PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 6.90 (-2.13%)
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 6.90 (-2.13%)
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

IGMS : 6.90 (-2.13%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 6.90 (-2.13%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - 14 minutes ago
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot